Korean diagnostics firm Noul signs 1st cervical cancer screening deal in Africa

Noul, a Seoul-based developer of artificial intelligence (AI)-powered blood and cancer diagnostic devices, has signed a supply agreement with a medical device distributor in East Africa to provide its cervical cancer screening and blood analysis solutions to four Indian Ocean island nations: Mauritius, Madagascar, Seychelles and Comoros, the company said Thursday. The deal marks the company’s first sale of a cervical cancer diagnostic product in Africa, where its business had previously centered on malaria testing. Noul said the agreement signals an expansion into higher-value cancer diagnostics on the continent. The company will supply its miLab CER cervical cancer screening device and miLab BCM blood analysis device under the deal. Both are built on Noul’s miLab platform, an all-in-one, point-of-care testing device that automates the full process of a microscope-based diagnosis — from preparing and staining a sample to digital imaging and AI-based analysis — and delivers lab-grade results in under 15 minutes, according to the company. Noul said the island nations targeted in the dea

Latest News from Korea

Latest Entertainment from Korea

Learn People & History of Korea